Latest news with #SecuritiesLitigationReformActof1995
Yahoo
11-06-2025
- Business
- Yahoo
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. 'It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon,' said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or follow us on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact:Pete Rahmerprahmer@ Media:Dan Budwick1AB973-271-6085dan@
Yahoo
19-05-2025
- Business
- Yahoo
Reading International, Inc. Announces Participation at the Sidoti Virtual Micro-Cap Investor Conference
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Reading International, Inc. (NASDAQ: RDI) ('Reading' or our 'Company'), an internationally diversified cinema and real estate company with operations and assets in the United States, Australia, and New Zealand, announced it is scheduled to participate at Sidoti's Virtual Micro-Cap Investor Conference taking place on Wednesday, May 21, through Thursday, May 22, 2025. Investor Relations contact, Andrzej Matyczynski, Executive Vice President – Global Operations, will present virtually at 10:45 A.M. Eastern time on Thursday, May 22, 2025. The presentation will provide insight on the Company's financial results for the fiscal first quarter ending March 31, 2025, business outlook and capital allocation strategy. The Company will also host virtual one-on-one investor meetings throughout both days of the conference. A copy of Company's investor presentation will become available on the Company's corporate website - Reading International - Events - on May 22, 2025 after the conclusion of the conference. Registration for the presentation or the one-on-ones will be available at Sidoti Public Registration. Registration is free and open to all; you do not need to be a Sidoti client. About Reading International, Inc. Reading International, Inc. (NASDAQ: RDI), an internationally diversified cinema and real estate company operating through various domestic and international subsidiaries, is a leading entertainment and real estate company, engaging in the development, ownership, and operation of cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. Reading's cinema subsidiaries operate under multiple cinema brands: Reading Cinemas, Consolidated Theatres and the Angelika brand. Its live theatres are owned and operated by its Liberty Theaters subsidiary, under the Orpheum and Minetta Lane names. Its signature property developments, including Newmarket Village in Brisbane, Australia, and 44 Union Square in New York City, are maintained in special purpose entities. Additional information about Reading can be obtained from our Company's website: Cautionary Note Regarding Forward-Looking Statements This release contains a variety of forward-looking statements as defined by the Securities Litigation Reform Act of 1995, including those related to (i) our expectations about the closing of the sale of our Wellington property assets and the subsequent lease of the existing cinema at Courtenay Central; and (ii) our intentions regarding the renovation and reopening of our existing cinema in the Courtenay Central building. You can recognize these statements by our use of words, such as 'may,' 'will,' 'expect,' 'believe,' 'intend' and 'anticipate' or other similar terminology. Given the variety and unpredictability of the factors that will ultimately influence our businesses and our results of operation, no guarantees can be given that any of our forward-looking statements will ultimately prove to be correct. Actual results may differ materially from those indicated in the forward-looking statements and there is no guarantee as to how our securities will perform either when considered in isolation or when compared to other securities or investment opportunities. Forward-looking statements made by us in this release are based only on information currently available to us and speak only as of the date on which they are made. We undertake no obligation to publicly update or to revise any of our forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. Accordingly, you should always note the date to which our forward-looking statements speak. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those factors discussed throughout Part I, Item 1A – Risk Factors – and Part II Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations – of our Annual Report on Form 10-K for the most recently ended fiscal year, as well as the risk factors set forth in any other filings made under the Securities Act of 1934, as amended, including any of our Quarterly Reports on Form 10-Q, for more information. For more information, contact:Gilbert Avanes – EVP, CFO, and TreasurerAndrzej Matyczynski – EVP Global Operations (213) 235-2240
Yahoo
16-05-2025
- Business
- Yahoo
Vuzix Smart Glasses Power Enterprise Deployments in Warehouse and Logistics for Major Multinational
ROCHESTER, N.Y., May 16, 2025 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of AI-powered smart glasses, waveguides, and Augmented Reality (AR) technologies, today acknowledged a public post made by Amazon on LinkedIn, which highlighted the use of Vuzix smart glasses to enhance warehouse operations. According to the post, the smart glasses are supporting Reliability and Maintenance Engineering (RME) teams by enabling "see what I see" functionality—allowing central experts to virtually diagnose and resolve complex equipment issues in real time. This approach is improving safety, accelerating repairs, and enhancing productivity within large-scale logistics facilities. Vuzix smart glasses have been purchased by the customer and are currently deployed to support maintenance operations and remote collaboration. "This is another clear example of how Vuzix smart glasses are delivering real-world value to some of the world's most sophisticated enterprises," said Paul Travers, President and CEO of Vuzix. "We're proud to support customers embracing wearable technologies to drive safety, efficiency, and digital transformation at scale." About Vuzix Corporation Vuzix is a leading designer, manufacturer and marketer of AI-powered Smart Glasses, Waveguides and Augmented Reality (AR) technologies, components and products for the enterprise, medical, defense and consumer markets. The Company's products include head-mounted smart personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality, as well OEM waveguide optical components and display engines. Vuzix holds more than 425 patents and patents pending and numerous IP licenses in the fields of optics, head-mounted displays, and the augmented reality wearables field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2024 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in: Rochester, NY; and Kyoto and Okayama, Japan. For more information, visit the Vuzix website, X and Facebook pages. Forward-Looking Statements Disclaimer Certain statements contained in this news release are "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward-looking statements contained in this release relate to Vuzix Smart Glasses, our business relationship and future business opportunities with Amazon, and among other things the Company's leadership in the Smart Glasses and AR display industry. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at or Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Vuzix Media and Investor Relations Contact: Ed McGregor, Director of Investor Relations,Vuzix Corporationed_mcgregor@ Tel: (585) 359-5985 Vuzix Corporation, 25 Hendrix Road, West Henrietta, NY 14586 USA,Investor Information – IR@ View original content to download multimedia: SOURCE Vuzix Corporation
Associated Press
16-04-2025
- Business
- Associated Press
Brookmount Gold Announces $2.1 Million Net Profit for Q1 2025
RENO, NV / ACCESS Newswire / April 16, 2025 / Brookmount Explorations, Inc (sic: 'Brookmount Gold') (OTC PINK:BMXI) is pleased to announce that its Indonesian operations reported much better than expected financial performance for the first quarter to February 28, 2025. Revenue was approximately $3.4 million with a net profit of $2.1 million or slightly over .01 Earnings per share (EPS). This highly positive transition to full operational control of the business, beginning in January, was reflective of a steadily increasing gold price and enhanced productivity as Brookmount's own mining activities were undergoing what has been a seamless restructuring under new management. 'We believe that this excellent result endorses our strategy of extracting maximum value from the takeover. We are increasing our staff and our efficiency to take our Indonesian operations to a new and higher level of performance,' commented CEO Nils Ollquist. Mr. Ollquist continued, 'This month, following recent work undertaken to increase the depth of the main shaft at our primary location to one hundred meter, we are adding an additional mining team of twenty workers to expand shift rotation, Reaching this depth will increase ore grades to above 20 grams/tonne of ore, and facilitate a minimum of three additional horizontal tunnels to be constructed to increase the mineable surface area.' Mr. Ollquist concluded, 'Our financial projection, based on existing ore grades and planned expansion of production, indicate our performance metrics are ahead of schedule and an endorsement of our decision to move forward with the takeover made last year. Free cash flow generated by our Indonesian operations will be allocated, as a priority, to eliminating the Company's remaining debt, to strengthening the balance sheet and improving our valuation. Further announcements on progress on accelerating Indonesian operations will be made over the few weeks.' About Brookmount Gold Founded in 2018, Brookmount Gold is a high-growth gold-producing company quoted on OTC Markets in the United States (OTC: BMXI). With operating gold mines in Southeast Asia and exploration and production assets in North America, the Company is focused on building production of existing assets to scale, in addition to acquiring and developing additional high quality gold assets with JORC/NI 43-101 verified resources. Safe Harbor Statements: Except for the historical information contained herein, certain of the matters discussed in this communication constitute 'forward-looking statements' within the meaning of the Securities Litigation Reform Act of 1995. Words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'anticipate,' 'estimate,' 'expect,' 'predict,' 'project,' 'future,' 'potential,' 'intend,' 'seek to,' 'plan,' 'assume,' 'believe,' 'target,' 'forecast,' 'goal,' 'objective,' 'continue' or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. These forward looking statements include, but are not limited to, statements regarding benefits of the proposed license, expected synergies, anticipated future financial and operating performance and results, including estimates of growth. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. For example, the expected timing and likelihood of completion of the pending transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the pending transaction that could reduce anticipated benefits or cause the parties to abandon the transaction, the ability to successfully integrate the businesses, the occurrence of any event, change or other circumstance that could give rise to the termination of the negotiations, the risk that the parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all, risks related to disruption of management time from ongoing business operations due to the proposed transaction, the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Brookmount's common stock. All such factors are difficult to predict and are beyond our control. We disclaim and do not undertake any obligation to update or revise any forward-looking statement in this report, except as required by applicable law or regulations. Investor Relations Contact: [email protected] or 410-825-3930 Website: Contact: [email protected] Social Links: Brookmount Gold X (Former Twitter): SOURCE: Brookmount Explorations, Inc. press release
Yahoo
14-02-2025
- Business
- Yahoo
F&M Bank Welcomes Carly Buchanan as Chief People Officer
Carly Buchanan, 2025 ARCHBOLD, Ohio, Feb. 14, 2025 (GLOBE NEWSWIRE) -- F&M Bank ('F&M'), an Archbold, Ohio-based bank owned by Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) is pleased to announce Carly Buchanan as its new Chief People Officer. With over 18 years of HR, leadership, and organizational development experience across multiple industries, Carly will lead F&M's Human Resources Department, driving strategic HR planning, talent acquisition, employee engagement, and organizational growth. Carly brings a decade of retail banking experience to her role, providing valuable insight into customer-focused strategies and operational efficiency. She holds senior HR certifications from SHRM (SHRM-SCP) and HRCI and has served as past President of the Northeast Indiana Human Resources Association. Recognized as a 2023 Fort Wayne 40 Under 40 honoree, Carly is also deeply committed to community involvement, supporting organizations like Junior Achievement, Boys and Girls Club, and the 988 Crisis Lifeline. 'Carly's leadership, expertise, and passion for people make her an incredible asset to F&M Bank,' said Lars Eller, President, and CEO. 'Her strategic vision will strengthen our culture, enhance employee engagement, and support our mission of serving our customers and communities.' Carly earned her MBA and a Bachelor of Science in Business Administration from Indiana Tech. She and her family reside in Northern Indiana, where she combines professional excellence with a strong dedication to community impact. About F&M Bank: F&M Bank is a local independent community bank that has been serving its communities since 1897. F&M Bank provides commercial banking, retail banking and other financial services. Our locations are in Butler, Champaign, Fulton, Defiance, Hancock, Henry, Lucas, Shelby, Williams, and Wood counties in Ohio. In Northeast Indiana, we have offices located in Adams, Allen, DeKalb, Jay, Steuben and Wells counties. The Michigan footprint includes Oakland County, and we have Loan Production Offices in Troy, Michigan; Muncie, Indiana; and Perrysburg and Bryan, Ohio. Safe harbor statementPrivate Securities Litigation Reform Act of 1995. Statements by F&M, including management's expectations and comments, may not be based on historical facts and are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Actual results could vary materially depending on risks and uncertainties inherent in general and local banking conditions, competitive factors specific to markets in which F&M and its subsidiaries operate, future interest rate levels, legislative and regulatory decisions, capital market conditions, or the effects of the COVID-19 pandemic, and its impacts on our credit quality and business operations, as well as its impact on general economic and financial market conditions. F&M assumes no responsibility to update this information. For more details, please refer to F&M's SEC filing, including its most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Such filings can be viewed at the SEC's website, or through F&M's website Company Contact: Investor and Media Contact: Lars B. EllerPresident and Chief Executive Officer Farmers & Merchants Bancorp, Inc.(419) 446-2501 leller@ Andrew M. BergerManaging DirectorSM Berger & Company, Inc. (216) 464-6400andrew@ A photo accompanying this announcement is available at in to access your portfolio
